



#### Contract n° 018486

# **NORMAN**

# Network of reference laboratories and related organisations for monitoring and bio-monitoring of emerging environmental pollutants

Co-ordination action

Priority 6.3 – Global Change and Ecosystems

# Deliverable: C.2.2. NSAID RESIDUES ANALYSIS IN WATER

Report on the 1st interlaboratory study (including statistical evaluation of the results and critical evaluation of the methodology used)

Due date of deliverable: April 2007 Actual submission date: April 2007

Start date of the project: 1<sup>st</sup> September 2005 Duration: 3 years

Work package leader: CSIC

Revision: final version

	Dissemination level	
PU	Public	Χ
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	1865
CO	Confidential, only for members of the consortium (including the Commission Services)	

Project funded by the European Commission within the 6<sup>th</sup> FP (2002-2006) Sub-priority 1.1.6.3 Global Change and Ecosystems

Co-ordinator: INERIS B.P. n°2 - 60550 - Verneuil-en-Halatte, France Internet: www.ineris.fr Tel. +33(0)3 44 55 66 77 fax +33(0)3 44 55 66 99



# Page 3 NORMAN Co-ordination Action



Contract N° 018486

# FIRST INTERLABORATORY STUDY ON NSAID RESIDUE ANALYSIS IN WATER



# **Contents**

I. Participant Laboratories: In alphabetical order	Erreur! Signet non défini.
II. Objectivese	3
III. General information	4
IV. Analytical protocols fro NORMAN participants	5
V. Results	6
VI. Summary of participants results	14
VII. Stability of the samples	17
VIII.Hierarchcal cluster analysis	20
IX.Conclusion	22
Anner	23



# Page 3 NORMAN Co-ordination Action



Contract N° 018486

# I. Participant Laboratories: In alphabetical order

- Environmental Institute, Kos, Slovak Republic
- Institute for Environment and Sustainability, JRC, Ispra, Italy
- Jozef Stefan Institute, Ljubljana, Slovenia
- CNRS, LPTC Université Bordeaux 1, Talence France
- Eawag, Environmental Chemistry, Duebendorf, Switzerland, EPF Lausanne, Switzerland
- Europa Fachhochschule Fresenius, University of Applied Science, Idstein, Germany
- Federal Institute of Hydrology (BFG), Kablenz, Germany
- IIQAB-CSIC, Barcelona, Spain
- Mario Negri Institute for Pharmacological Research, Milan, Italy
- Pesticide Residues Laboratory, General Chemical State Laboratory, Athens, Greece
- Umweltbundesamt GmbH, Abt. Umweltwirksame Stoffe und Metaboliten, Wien, Austria.
- Universidade de Santiago de Compostela, Spain
- Universita "La Sapienza" di Roma, Italy

# II. Objectives

The main objectives were:

To carry out the first validation level of chromatographic methods of analysis of Ketoprofen, Naproxen, Ibuprofen and Diclofenac.

To evaluate the main sources of variation

To evaluate the possible significant differences between methods based on Liquid chromatography and gas chromatography.

To assess the influence of sample matrix on the different chromatographic approaches To assess stability of samples



# Page 4 NORMAN Co-ordination Action



Contract N° 018486

# **III. General Information**

NSAID compounds selected in this study were: Ketoprofen, Naproxen, Ibuprofen and Diclofenac.

Participants were requested to analyse these compounds in each sample.

Each participant received three batches of samples and each batch was composed by 3 samples:

- a natural sample of wastewater
- a fortified river sample
- spiked MilliQ water

A total number of 162 samples were distributed to 17 laboratories distributed along 11 European Countries (Austria, France, Germany, Greece, Italy, Norway, Slovak Republic, Slovenia, Spain, Switzerland, and UK) that initially took part on the exercise. A final number of 14 participations concluded the ring exercise.

In order to minimize the sources of variation all samples were collected transported, homogenised and prepared at the same time in a central laboratory (Environmental Chemistry Department, IIQAB-CSIC, Barcelona).

Samples were collected and prepared during the first week of September 2006.

All water samples were filtered through 0.7 and 0.45  $\mu m$  glass micro-fibre filters to remove suspended matter and they were homogenized in a polyethylene bucked.

The samples were sent refrigerated.

Each participant received approximately 1,1 L of each sample. Participants were requested to measure and annotate the temperature of samples at reception. Most of participant received theirs samples in the range of 15-20 °C. Participant were also requested to keep the samples under freezing conditions until the extraction of each batch, according to the dates indicated below.

Deadline for chromatographic analysis was November 17<sup>th</sup>, and the deadline for sending the results November 24<sup>th</sup>.

Samples were sent codified according to the table, but the wastewater samples were indicated to the participants.

	SPE Dates	SAMPLE CODES		
Batch 1	25-29 Sep 2006	A1	B1	C1
		Fortified river water	Wastewater	Fortified Milli Q
				water
Batch 2	9-3 Oct 2006	A2	B2	C2
		Wastewater	Fortified Milli Q	Fortified river
			water	water
Batch 3	23-27 Oct 2006	A3	B3	C3
		Fortified Milli Q	Fortified river	Wastewater
		water	water	

In order to maintain the anonymous character of each participant, an identification number was provided to each laboratory and they were requested to use it for results presentation.



# Page 5 NORMAN Co-ordination Action



Contract N° 018486

# **IV. Analytical Protocols for NORMAN participants**

#### **Validation**

Norman participants were requested to use one of the follow methods.

# **LC-MS Analytical Protocol**

Extraction and Pre-treatment

Neutral pH

Extraction Volumes: 500 mL of MilliQ water and river samples

200 mL of wastewater effluent

SPE using Oasis HLB (60 mg, 3mL) polymeric cartridges.

Elution of cartridges with methanol

Reconstitution of extracts: 1mL of methanol-water (25:75, v/v).

LC-ESI-tandem MS analysis

Analysis of extracts: LC-ESI-tandem MS Chromatographic separation: RP-18 column.

Analysis under NI mode, using as eluent A methanol and water as eluent B.

2 transitions, one for identification and one for quantification





# Page 6 NORMAN Co-ordination Action



Contract N° 018486

#### **GC-MS Analytical Protocol**

Int. std.: d3 ibuprofen SPE: Oasis HLB/60 mg

Elution: EtAc

Derivatisation: MTBSTFA (MSTFA)

SIM ions (IB:263, NP:287, KT:311, DF:352&354) GC column: HP-5MS, 30m, 0.25mm, 0,25microm

GC oven: 65° (2min), rate 30°/min to 180°, rate 5°/min to 300 (hold 12 min)

# V. Results

A total number of 126 samples were analyzed along the ring exercise and 486 results were collected corresponding to 14 participations in 13 laboratories.

Total No. Results = 486

Total No. Outliers = 23 (4.7%)

No. of participations using Liquid Chromatography = 7 (50%) No. of participations using Gas Chromatography = 7 (50%)

No. of outliers using Liquid Chromatography = 8 (3.3% of results) No. of outliers using Gas Chromatography = 15 (6.1 % of results)

For each series of samples (batch 1, batch2, and batch3) the initial mean value (Xi), the initial standard deviation ( $\sigma$ i), the upper warning limit (UWL), and the lower warning limit (LWL) values were calculated.

The limits were calculated as:  $UWL = (Xi+2 \sigma i)$ , and  $LWL = (Xi-2 \sigma i)$ 

As acceptance criteria for each result was used the *Z-score* function according to the Laboratory Accreditation & Audit Protocol: Food Inspection Directorate":

 $Z = (X_{lab}-Xi) / \sigma i$ 

Where  $X_{\text{lab}}$  is a result, Xi is the initial mean value and the  $\sigma$ i the initial standard deviation.

The results whose *Z*-value was over 3 was directly excluded and when the *Z*-score value was between 2 and 3 was applied the Dixon test with a 5% of significance level.


On Figure 1 are presented the *Z-score* values for each result of each participant.


In a second step the outlier values were excluded of data treatment the statistical parameters (mean value (Xi), standard deviation ( $\sigma$ i), variance ( $\sigma$ <sup>2</sup>), coefficient of variation (%CV) were calculated



# Page 7 NORMAN Co-ordination Action












# Page 8 NORMAN Co-ordination Action













# Page 9 NORMAN Co-ordination Action











# Page 10 NORMAN Co-ordination Action









# Page 11 NORMAN Co-ordination Action



Contract N° 018486

On Table 1 are summarized the corrected results (after outlier exclusion) obtained for each compound in the different types of samples along the exercise.

# Ketoprofen

	Group	No.	Mean	Standard	Standard	Median	Minimum	Maximum	95%	Confidence	No.	of
Wastewater		accepted		deviation	error of		value	value	Interval		outliers	
		results			mean				From	То		
	Batch 1	13	678.77	282.23	78.27	800.00	25	1090	508.21	849.33	0	
	Batch 2	12	601.08	235.24	67.91	620.95	112	897	451.61	750.54	1	
	Batch 3	13	642.55	303.61	84.21	662.00	144	1200	459.06	826.03	1	

Fortified river	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value	95% Interval	Confidence	No. outliers	of
water		results			mean				From	То		
Fortification	Batch 1	13	238.73	121.08	33.58	200	73	461	165.56	311.90	0	
290 ng/L	Batch 2	13	297.92	134.13	37.20	260	62	538	216.85	378.98	0	
	Batch 3	12	241.39	92.317	26.65	230	106.2	420	182.74	300.05	1	

Fortified	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value	95% Interval	Confidence	No. outliers	of
MilliQ water		results			mean				From	То		
Fortification	Batch 1	12	164.24	99.52	28.73	133.5	64	365	101	227.47	0	
83 ng/L	Batch 2	11	101.71	40.52	12.22	100.0	60	208.8	74.49	128.93	1	
_	Batch 3	11	97.35	33.96	10.24	91.00	37	151	74.54	120.17	0	

# **Naproxen**

	Wastewater	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value		nfidence rval	No. of outliers
			results			mean				From	То	
	ĺ	Batch 1	12	913.18	744.55	214.93	848.00	18	2140	440.11	1386.3	1
		Batch 2	13	858.17	635.68	176.31	887.00	77	1790	474	1242.3	0
L		Batch 3	13	818.54	603.27	167.32	930.00	77	1800	153.95	1183.1	0

Fortified river	Group	No. accepted	Mean	Standard deviation	Standard error of mean	Median	Minimum value	Maximum value	95% Co Inte	nfidence rval	No. of outliers
water		results							From	То	
Fortification	Batch 1	13	1109.0	845.51	234.50	1430.0	53	24.37	598.01	1620	0
1124 ng/L	Batch 2	12	1088.9	746.59	215.52	1047.5	308	2446	614.51	15.63	1
	Batch 3	13	1066.6	764.33	211.99	1230.0	53.5	2325	604.69	1528	0

Fortified	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value	95% Interval	Confidence	No. outliers	of
MilliQ water		results			mean				From	То		
Fortification	Batch 1	11	174.32	96.214	29.010	200.00	51	330	109.68	238.95	2	
266 ng/L	Batch 2	12	158.83	96.254	27.786	165.00	33.5	327	97.68	219.99	1	
	Batch 3	12	201.96	106.87	30.850	225.00	24	369	134.06	269.86	1	

Table 1 (1/2)



# Page 12 NORMAN Co-ordination Action



Contract N° 018486

# <u>Ibuprofen</u>

Wastewater	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value		nfidence rval	No. of outliers
		results			mean				From	То	
	Batch 1	13	1834.2	640.75	177.71	1980.0	233	2680	1446.9	2221.4	1
	Batch 2	14	1777.6	589.47	157.54	1715.5	645	2951.5	1437.3	2117.9	0
	Batch 3	13	1918.3	385.03	106.79	1904.0	1124	1685.5	1685.6	2151.0	1

Fortified river	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value		nfidence erval	No. of outliers
water		results			mean				From	То	
Fortification	Batch 1	14	536.04	278.79	74.510	508.75	22	1067.1	375.1	699.0	0
675 ng/L	Batch 2	13	523.73	156.46	43.395	484.00	310	875.0	429.2	618.3	1
	Batch 3	13	542.74	190.58	52.859	603.00	278	811.1	427.6	657.9	1

	Group	No.	Mean	Standard	Standard	Median	Minimum	Maximum	95%	Confidence	No.	of
Fortified		accepted		deviation	error of		value	value	Interval		outliers	
MilliQ water		results			mean				From	То		
Fortification	Batch 1	13	260.46	139.51	38.693	215.00	66	621	176.15	344.8	1	
225 ng/L	Batch 2	13	253.15	102.87	28.532	246.00	165	547	190.97	315.3	1	
, and the second	Batch 3	13	206.12	45.461	12.609	203.00	96	265	178.65	233.6	1	

# **Diclofenac**

Wastewater	Group	No. accepted	Mean	Standard deviation	Standard error of	Median	Minimum value	Maximum value		nfidence erval	No. of outliers
		results			mean				From	То	
	Batch 1	14	1482.2	784.75	209.73	1545.0	92	2557	1029.2	1935.2	0
	Batch 2	14	1476.4	919.93	245.86	1564.5	177	2920	945.29	2007.4	0
	Batch 3	14	1503.8	982.03	262.46	1457.0	177	3343	936.84	2070.7	0

	Group	No.	Mean	Standard	Standard	Median	Minimum	Maximum		nfidence	No. of
Fortified river		accepted		deviation	error of		value	value		rval	outliers
water		results			mean				From	То	
Fortification	Batch 1	11	400.36	198.83	59.951	340.00	133	767	266.79	533.93	1
398 ng/L	Batch 2	11	408.27	145.78	43.955	457.00	129	609	310.34	506.21	1
	Batch 3	12	392.88	157.37	45.428	400.00	154	705	292.89	492.86	2

	Group	No.	Mean	Standard	Standard	Median	Minimum	Maximum	95%	Confidence	No.	of
Fortified		accepted		deviation	error of		value	value	Interval		outliers	
MilliQ water		results			mean				From	То		
Fortification	Batch 1	13	205.71	109.18	30.280	193.00	61	483.2	139.73	271.69	1	
200 ng/L	Batch 2	14	167.43	79.237	21.177	156.00	61.4	284	121.69	213.17	0	
	Batch 3	14	150.51	71.030	19.700	148.00	33	320	107.58	193.43	1	

Table 1 (2/2)



# Page 13 NORMAN Co-ordination Action



Contract N° 018486

On table 2 are summarized the mean of each compound in each type of water samples.

	Mean of batches	Standard deviation of batch
Wastewater		
Ketoprofen	640.8	38.9
Naproxen	863.3	47.5
Ibuprofen	1843.4	70.8
Diclofenac	1487.4	14.4
Fortified river water		
Ketoprofen	259.3	33.4
Naproxen	1088.2	21.2
Ibuprofen	534.2	9.6
Diclofenac	400.5	7.7
Fortifiend MilliQ wa	ter	
Ketoprofen	121.1	37.4
Naproxen	178.4	21.8
Ibuprofen	239.9	29.5
Diclofenac	174.55	28.3




# Page 14 NORMAN Co-ordination Action





Contract N° 018486


# VI. Summary of participant's results

The summary of the results obtained for each participant in front of the mean value of the results is summarized on Figure















# Page 15 NORMAN Co-ordination Action

















# Page 16 NORMAN Co-ordination Action













# Page 17 NORMAN Co-ordination Action



Contract N° 018486

# VII. Stability of the samples

In order to establish the stability of samples along this intercomparison test, differences between variances obtained for every type of sample at different intervals were evaluated.


The Analysis of Variance for each compound is presented in Annex I.


In all cases the distribution of results followed a Gaussian distribution.

The results from the normality and Bartlett's tests are presented in Annex I.

In two cases, results from Bartlett's test suggest that the differences among standard deviation were significant along the exercise. These cases were Ketoprofen and Ibuprofen (see figure 3) in Milli Q water. This sample has a basic pH, and that probably influenced on the stability of these compounds.

For the rest of the cases good stability was obtained along the exercise.







# Page 18 NORMAN Co-ordination Action



Contract N° 018486

# Reproducibility and repeatability:

The measurement of precision of each laboratory to repeat the measurements on a sample at different intervals (batch): reproducibility (R) was calculated as:

$$R = \frac{\sum r_{lab}}{N}$$

Where

$$r_{lab} = \Sigma (2.2^{1/2}) \sigma_{lab}$$

N= number of samples (only results for stable samples were accounted)  $\sigma_{lab}$  is the standard deviation between results from the same laboratory on a stable sample at different intervals.

Repeatability values obtained for the four measurements (Ketoprofen, naproxen, ibuprofen, and diclofenac) for river water and wastewater are summarized on tables 3 and 4. On Figure

Table 3: Repeatability (r) and reproducibility (R) values of each laboratory for the analysis of Ketoprofen, naproxen, ibuprofen and diclofenac in wastewater.

	Ketoprofen	Naproxen	Ibuprofen	Diclofenac
01 LC	356	488	546	113
02 GC	455	186	805	1978
03 LC	237	386	747	727
03 GC	220	704	645	1086
04 GC	133	233	898	792
05 LC	335	436	565	900
06 LC	174	96	1261	684
08 GC	752	217	495	469
10 GC	131	572	200	453
11 LC	311	1366	1018	253
12 LC	66	94	1166	226
13 LC	14	0	307	85
15 LC	0	0	309	1492
17 GC	368	412	621	1218
R	254	371	684	748



### Page 19 NORMAN Co-ordination Action




Contract N° 018486

Table 4: Repeatability (r) and reproducibility (R) values of each laboratory for the analysis of Ketoprofen, naproxen, ibuprofen and diclofenac in river water.

	Ketoprofen	Naproxen	Ibuprofen	Diclofenac
01 LC	28	795	314	888
02 GC	308	143	257	726
03 LC	75	613	128	361
03 GC	328	891	99	281
04 GC	49	191	211	597
05 LC	298	1704	733	2074
06 LC	59	149	1065	3013
08 GC	92	61	169	478
10 GC	33	65	97	273
11 LC	397	997	512	1448
12 LC	178	462	47	133
13 LC	153	368	773	2188
15 LC			700	1980
17 GC	656	2242	235	664
R	204	668	381	1079

When "r" is superior to the Upper Warning Limit the variation coefficient for this laboratory should be considered significant. This coefficient is inversely proportional to the precision, which means a repeatability level significant lower than the rest.

On Figure 4 the repeatability coefficients (r) and coefficients of variation intra-laboratories are shown for the most complex matrix. Must be said that for ketoprofen one laboratory presented a significant superior variation coefficient and lower precision, laboratory number 8. For Naproxen a significant lower precision was showed by participant number 11, and for diclofenac laboratory number 2 showed a significant degree of variation..



VIII. Hierarchical cluster analysis



### Page 20 NORMAN Co-ordination Action



Contract N° 018486

The possible interrelation between results was studied using the hierarchical cluster analysis. So as to all the results for each type of water were studied together and the results for each participant were grouped first according the Average Linkage Cluster method, and second according to the Nearest Neighbor Cluster method. In both cases the measure interval between results was the squared Euclidean distance.

Both cluster analysis concluded that the results of participating laboratories are independent of the analytical method used for the analysis of the samples (LC or GC).

On the other hand, no relation was obtained with the results and the temperature of the samples at reception in the range of temperatures studied.

On figure 4 Dendograms corresponding to the cluster analysis using the single linkage method are represented.

#### RIVER WATER

Dendrogram using Single Linkage




Figure 4(1/2)



# Page 21 NORMAN Co-ordination Action




Contract N° 018486

#### Wastewater

Dendrogram using Single Linkage


#### Rescaled Distance Cluster Combine



#### Milli-Q

Dendrogram using Single Linkage

#### Rescaled Distance Cluster Combine





# Page 22 NORMAN Co-ordination Action



Contract N° 018486

# **IX. Conclusions:**

The number of participants that initiated this interlaboratory exercise was 17, and the final number of participants was 13 (77%).

The final number of results collected was 486 and 23 values were outliers (4,7%), and were discarded.

The number of outlier values by liquid chromatography was 8 (3,3% of results), whereas the number of outlier using gas chromatography was superior 15 (6,1%), as expected because of the necessary additional step (derivatization).

Four laboratories obtained the higher number of outlier values: laboratory 11, 15, 17, and 2 with 7, 4, 3 and 3 outliers respectively.

The sample with higher number of outlier was the fortified MilliQ water, because the level of concentration was lower.

The second sample with more outlier values was wastewater due to the complexity of the matrix. Also for this sample were obtained the higher levels of variability.

The stability of samples were followed along the exercise by means of the Analysis of variance. In all cases ANOVA showed good stability for the NSAID selected in this study, and the variations among means were not significantly greater than expected by chance, with exception of Ketoprofen and Ibuprofen in the Milli-Q water, probably due to the basic pH of this sample, and the low level of concentrations.

A general good agreement was obtained between the concentrations of fortification and the mean values recorded by the participants. However, the precision of individual participants was low along the exercise, and that means a necessary protocol of sample treatment including (manipulations, how to defreeze the samples and during how long, etc...) in order to minimize sources of variation in the second ring.

About reproducibility of values recorded for the analyzed compound in the different types of samples was as well low, but that was expected due the high number of small different methods involved in the present edition.

The hierarchical cluster analysis concluded that no relation can be found between the results and if the samples were analyzed following a GC or a LC based method.

In addition no relation was obtained between the results and the temperature at reception.



# Page 23 NORMAN Co-ordination Action



Contract N° 018486

# **ANNEX**



### Page 24 NORMAN Co-ordination Action



Contract N° 018486

# Ketoprofen wastewater

#### **One-way Analysis of Variance (ANOVA)**

The P value is 0.7826, considered not significant.

Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 0.7237 The P value is 0.6964.

Bartlett's test suggests that the difference among the SDs is not significant.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Valu	ie Passed	normality test?
========		=====	= ======	======
batch 1	0.204	7 >0.10	) Yes	
batch 2	0.179	5 >0.10	) Yes	
batch 3	0.197	9 >0.10	) Yes	

#### Intermediate calculations. ANOVA table

Source of	Degrees of	Sum of	Mean
variation	freedom	squares	square
=======================================	=======================================	======	====
Treatments (between columns)	2	37677	18838
Residuals (within columns)	35	2670699	76306
Total	37	2708376	

F = 0.2469 =(MStreatment/MSresidual)



# Page 25 NORMAN Co-ordination Action



Contract N° 018486

# River water - Ketoprofen

#### **One-way Analysis of Variance (ANOVA)**

The P value is 0.3658, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 1.521 The P value is 0.4675.

Bartlett's test suggests that the differences among the SDs is not significant.

### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
=======	=====	=====	=======================================
Batch1	0.163	39 >0.10	Yes
Batch2	0.149	97 >0.10	Yes
Batch3	0.211	1 >0.10	Yes

#### Intermediate calculations. ANOVA table

Source of	Degree	es of Sum of	Mean
variation	freed	om squares	square
=======================================	=======================================	=======================================	=====
Treatments (between columns)	2	28723	14362
Residuals (within columns)	35	485565	13873
Total	37	514289	

F = 1.035 =(MStreatment/MSresidual)



# Page 26 NORMAN Co-ordination Action



Contract N° 018486

# Ketoprofen MilliQ water

### **One-way Analysis of Variance (ANOVA)**

The P value is 0.0364, considered significant.

Variation among column means is significantly greater than expected by chance.

Tukey-Kramer Multiple Comparisons Test If the value of q is greater than 3.482 then the P value is less than 0.05.

Comparison	Mean Difference	q P value	
Batch 1 vs Batch 2 Batch 1 vs Batch 3 Batch 2 vs Batch 3	62.533 3.188 66.887 3.410 4.355 0.2173	0 ns P>0.05	
Difference	Mean	95% Confidenc	e Interval
	Difference	From	To
Batch 1 - Batch 2 Batch 1 - Batch 3 Batch 2 - Batch 3	62.533	-5.756	130.82
	66.887	-1.401	135.18
	4.355	-65.402	74.112

#### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 13.838

The P value is 0.0010.

Bartlett's test suggests that the differences among the SDs is extremely significant.

Since ANOVA assumes populations with equal SDs, you should consider transforming your data (reciprocal or log) or selecting a nonparametric test.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?	
========	====	=====	=======================================	==
Batch 1	0.191	2 >0.10	Yes	
Batch 2	0.246	88 >0.10	Yes	
Batch 3	0.164	3 >0.10	Yes	



# Page 27 NORMAN Co-ordination Action



Contract N° 018486

# Intermediate calculations. ANOVA table

Source of variation	Degrees of freedom	Sum of squares	Mean square
	==== ======		=====
Treatments (between columns)	2	32618	16309
Residuals (within columns)	31	136890	4415.8
Total	33	169508	

F = 3.693 =(MStreatment/MSresidual)



### Page 28 NORMAN Co-ordination Action



Contract N° 018486

# Naproxen - Wastewater

#### One-way Analysis of Variance (ANOVA)

The P value is 0.9379, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 0.5417

The P value is 0.7627.

Bartlett's test suggests that the differences among the SDs is not significant.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group KS P Value Passed normality test?
Batch 1 0.1903 > 0.10 Yes
Batch 2 0.1916 > 0.10 Yes

Batch 3 0.1896 > 0.10 Yes

#### Intermediate calculations. ANOVA table

Source of	Degrees of	Sum of	Mean
variation	freedom	squares	square
=======================================	=======================================	==========	=====
Treatments (between columns)	2	56183	28092
Residuals (within columns)	35	1.531E+07	437552
Total	37	1.537E+07	

F = 0.06420 = (MStreatment/MSresidual)



# Page 29 NORMAN Co-ordination Action



Contract N° 018486

# Naproxen - river

#### One-way Analysis of Variance (ANOVA)

The P value is 0.9906, considered not significant.

Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

#### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 0.2009

The P value is 0.9044.

Bartlett's test suggests that the differences among the SDs is not significant.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
==========	====== ==	====== ==	
Batch1	0.2471 >	0.10	Yes
Batch2	0.2206 >	0.10	Yes
Batch3	0.2130 >	0.10	Yes

#### Intermediate calculations, ANOVA table

Source of	Degrees of	f Sum of	Mean
variation	freedom	squares	square
=======================================	=======================================	======= ===	=====
Treatments (between columns)	2	11686	5843.2
Residuals (within columns)	35	2.172E+07	620586
Total	37	2.173E+07	

F = 0.009416 =(MStreatment/MSresidual)



# Page 30 NORMAN Co-ordination Action



Contract N° 018486

# Naproxen - MilliQ water

#### **One-way Analysis of Variance (ANOVA)**

The P value is 0.5702, considered not significant.

Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

#### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 0.1553

The P value is 0.9253.

Bartlett's test suggests that the differences among the SDs is not significant.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
==========	===========	========	
Batch1	0.2014 >	0.10	Yes
Batch2	0.1930 >	0.10	Yes
Batch3	0.1519 >	0.10	Yes

#### Intermediate calculations, ANOVA table

Source of	Degrees of	Sum of	Mean
variation	freedom	squares	square
=======================================	=======================================		=====
Treatments (between columns)	2	11437	5718.6
Residuals (within columns)	32	320109	10003
Total	34	331546	

F = 0.5717 = (MStreatment/MSresidual)



# Page 31 NORMAN Co-ordination Action



Contract N° 018486

# Wastewater - Ibuprofen

One-way Analysis of Variance (ANOVA)

The P value is 0.8021, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 3.080 The P value is 0.2143.

Bartlett's test suggests that the differences among the SDs is not significant.

#### Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
	======	===========	
Batch1	0.2332	> 0.10	Yes
Batch2	0.1520	> 0.10	Yes
Batch3	0.07681	> 0.10	Yes

### Intermediate calculations. ANOVA table

Source of	Degrees of	Sum of	Mean
variation	freedom	squares	square
=======================================	=======================================	=======================================	=====
Treatments (between columns)	2	134590	67295
Residuals (within columns)	37	1.122E+07	303322
Total	39	1.135E+07	

F = 0.2219 =(MStreatment/MSresidual)



# Page 32 NORMAN Co-ordination Action



Contract N° 018486

# **Ibuprofen-river**

### One-way Analysis of Variance (ANOVA)

The P value is 0.9746, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

#### Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 4.249
The P value is 0.1195.
Bartlett's test suggests that the differences among the SDs is not significant.

Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
========		=====	=======================================
Batch1	0.172	26 > 0.10	Yes
Batch2	0.201	8 >0.10	Yes
Batch3	0.188	39 > 0.10	Yes

Intermediate calculations. ANOVA table

Source of variation	Degrees of freedom			
Treatments (between Residuals (within colu	,		====== 2420.2 1740036	======
Total	39 174	2456		

F = 0.02573 =(MStreatment/MSresidual



# Page 33 NORMAN Co-ordination Action



Contract N° 018486

# <u>Ibuprofen - Milliq water</u>

One-way Analysis of Variance (ANOVA)

The P value is 0.3584, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 12.245

The P value is 0.0022.

Bartlett's test suggests that the differences among the SDs is very significant.

Since ANOVA assumes populations with equal SDs, you should consider transforming your data (reciprocal or log) or selecting a nonparametric test.

Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
========		=====	=======================================
Batch1	0.234	6 >0.10	Yes
Batch2	0.206	32 > 0.10	Yes
Batch3	0.205	59 >0.10	Yes

Intermediate calculations, ANOVA table

Source	9	es of Sum			
variatio	n freedon	n squares	squar	е	
=======		===== ==	======	========	= ======
Treatments	(between columns	3) 2	22609	11304	
Residuals (v	vithin columns)	36 3	85352	10704	
Total	38	407961			
F = 1.056 =	(MStreatment/MS	residual)			



# Page 34 NORMAN Co-ordination Action



Contract N° 018486

# Wastewater-diclofenac

One-way Analysis of Variance (ANOVA)

The P value is 0.9964, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 0.6469 The P value is 0.7237. Bartlett's test suggests that the differences among the SDs is not significant.

Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
========		=====	=======================================
Batch1	0.189	00 >0.10	Yes
Batch2	0.150	08 > 0.10	Yes
Batch3	0.132	22 > 0.10	Yes

Intermediate calculations. ANOVA table

	Source of variation	Degrees of freedom				
	tments (between duals (within colu		39	_	====== 5829.4 154E+07	 ======
Tota	 I	41 3.15	55E+	⊦07		

F = 0.003604 =(MStreatment/MSresidual)



# Page 35 NORMAN Co-ordination Action



Contract N° 018486

# **Diclofenac -river**

One-way Analysis of Variance (ANOVA)

The P value is 0.9763, considered not significant. Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 1.049
The P value is 0.5920.
Bartlett's test suggests that the differences among the SDs is not significant.

Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

	Group	KS	P Value	Passe	d normality	test?		
:		====	=====	=====	==== ====		=======	:===
	Batch1	0.164	7 >0.10	Yes				
	Batch2	0.176	3 >0.10	Yes				
	Batch3	0.157	'8 <b>&gt;</b> 0.10	Yes				

Intermediate calculations. ANOVA table

Source of

variation	freedom				
	======	==== ==	======	== ======	= ======
Treatments (between Residuals (within columns)	,		1360.8 380291	680.40 28396	
Total	33 8	381652			

Degrees of Sum of Mean

F = 0.02396 =(MStreatment/MSresidual)



### Page 36 NORMAN Co-ordination Action



Contract N° 018486

# **Diclofenal MilliQ**

One-way Analysis of Variance (ANOVA)

The P value is 0.2712, considered not significant.

Variation among column means is not significantly greater than expected by chance.

Post tests were not calculated because the P value was greater than 0.05.

Assumption test: Are the standard deviations of the groups equal?

ANOVA assumes that the data are sampled from populations with identical SDs. This assumption is tested using the method of Bartlett.

Bartlett statistic (corrected) = 2.434 The P value is 0.2962. Bartlett's test suggests that the differences among the SDs is not significant.

Assumption test: Are the data sampled from Gaussian distributions?

ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption is tested using the method Kolmogorov and Smirnov:

Group	KS	P Value	Passed normality test?
========	====	=====	=======================================
Batch1	0.184	14 >0.10	Yes
Batch2	0.145	59 >0.10	Yes
Batch3	0.206	80 >0.10	Yes

Intermediate calculations. ANOVA table

Source of	Degree	es of S	um c	of Mea	an		
variation	freedon	n squa	ares	squar	е		
=======================================		=====	===	=====	== =====	===	=======
Treatments (between Residuals (within colu		,	_	20844 5199	10422 7708.1		
Total	39	30604	3				

F = 1.352 =(MStreatment/MSresidual)